GLARIUS-Trial (randomized phase 2 study of bevacizumab/irinotecan therapy versus standard therapy in the primary treatment of newly diagnosed MGMT-unmethylated glioblastoma)
DIRECTOR-Trial (dose-intensified re-exposure with temozolomide in alternating weeks versus temozolomide in alternating three weeks of therapy and one week off therapy in recurrent glioblastoma)
NOA-24/MecMeth-Trial (phase 1/2 study of combined therapy with meclofenamate and temozolozomide in the first recurrence of MGMT-methylated glioblastoma)
